244 related articles for article (PubMed ID: 23889305)
21. Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting.
Matar P; Rojo F; Cassia R; Moreno-Bueno G; Di Cosimo S; Tabernero J; Guzmán M; Rodriguez S; Arribas J; Palacios J; Baselga J
Clin Cancer Res; 2004 Oct; 10(19):6487-501. PubMed ID: 15475436
[TBL] [Abstract][Full Text] [Related]
22. Transforming growth factor alpha expression drives constitutive epidermal growth factor receptor pathway activation and sensitivity to gefitinib (Iressa) in human pancreatic cancer cell lines.
Pino MS; Shrader M; Baker CH; Cognetti F; Xiong HQ; Abbruzzese JL; McConkey DJ
Cancer Res; 2006 Apr; 66(7):3802-12. PubMed ID: 16585207
[TBL] [Abstract][Full Text] [Related]
23. Epidermal growth factor receptor inhibitors enhance susceptibility to Fas-mediated apoptosis in oral squamous cell carcinoma cells.
Iwase M; Takaoka S; Uchida M; Yoshiba S; Kondo G; Watanabe H; Ohashi M; Nagumo M
Oral Oncol; 2008 Apr; 44(4):361-8. PubMed ID: 17689285
[TBL] [Abstract][Full Text] [Related]
24. Evaluation of the therapeutic potential of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib in preclinical models of bladder cancer.
Dominguez-Escrig JL; Kelly JD; Neal DE; King SM; Davies BR
Clin Cancer Res; 2004 Jul; 10(14):4874-84. PubMed ID: 15269164
[TBL] [Abstract][Full Text] [Related]
25. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.
Huang S; Armstrong EA; Benavente S; Chinnaiyan P; Harari PM
Cancer Res; 2004 Aug; 64(15):5355-62. PubMed ID: 15289342
[TBL] [Abstract][Full Text] [Related]
26. Improving gelation efficiency and cytocompatibility of visible light polymerized thiol-norbornene hydrogels via addition of soluble tyrosine.
Shih H; Liu HY; Lin CC
Biomater Sci; 2017 Feb; 5(3):589-599. PubMed ID: 28174779
[TBL] [Abstract][Full Text] [Related]
27. Molecularly engineered PEG hydrogels: a novel model system for proteolytically mediated cell migration.
Raeber GP; Lutolf MP; Hubbell JA
Biophys J; 2005 Aug; 89(2):1374-88. PubMed ID: 15923238
[TBL] [Abstract][Full Text] [Related]
28. In situ forming hydrogels via catalyst-free and bioorthogonal "tetrazole-alkene" photo-click chemistry.
Fan Y; Deng C; Cheng R; Meng F; Zhong Z
Biomacromolecules; 2013 Aug; 14(8):2814-21. PubMed ID: 23819863
[TBL] [Abstract][Full Text] [Related]
29. AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity.
Traxler P; Allegrini PR; Brandt R; Brueggen J; Cozens R; Fabbro D; Grosios K; Lane HA; McSheehy P; Mestan J; Meyer T; Tang C; Wartmann M; Wood J; Caravatti G
Cancer Res; 2004 Jul; 64(14):4931-41. PubMed ID: 15256466
[TBL] [Abstract][Full Text] [Related]
30. Knockdown of the Bcl-2 gene increases sensitivity to EGFR tyrosine kinase inhibitors in the H1975 lung cancer cell line harboring T790M mutation.
Zou M; Xia S; Zhuang L; Han N; Chu Q; Chao T; Peng P; Chen Y; Gui Q; Yu S
Int J Oncol; 2013 Jun; 42(6):2094-102. PubMed ID: 23588221
[TBL] [Abstract][Full Text] [Related]
31. Antitumor activity of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib (ZD1839, Iressa) in non-small cell lung cancer cell lines correlates with gene copy number and EGFR mutations but not EGFR protein levels.
Helfrich BA; Raben D; Varella-Garcia M; Gustafson D; Chan DC; Bemis L; Coldren C; Barón A; Zeng C; Franklin WA; Hirsch FR; Gazdar A; Minna J; Bunn PA
Clin Cancer Res; 2006 Dec; 12(23):7117-25. PubMed ID: 17145836
[TBL] [Abstract][Full Text] [Related]
32. Photoclick Hydrogels Prepared from Functionalized Cyclodextrin and Poly(ethylene glycol) for Drug Delivery and in Situ Cell Encapsulation.
Shih H; Lin CC
Biomacromolecules; 2015 Jul; 16(7):1915-23. PubMed ID: 25996903
[TBL] [Abstract][Full Text] [Related]
33. Blockage of epidermal growth factor receptor by quinazoline tyrosine kinase inhibitors suppresses growth of human hepatocellular carcinoma.
Liu Y; Poon RT; Shao W; Sun X; Chen H; Kok TW; Fan ST
Cancer Lett; 2007 Apr; 248(1):32-40. PubMed ID: 16837130
[TBL] [Abstract][Full Text] [Related]
34. Effect of macromer weight percent on neural cell growth in 2D and 3D nondegradable PEG hydrogel culture.
Lampe KJ; Mooney RG; Bjugstad KB; Mahoney MJ
J Biomed Mater Res A; 2010 Sep; 94(4):1162-71. PubMed ID: 20694983
[TBL] [Abstract][Full Text] [Related]
35. Biomimetic hydrogels for chondrogenic differentiation of human mesenchymal stem cells to neocartilage.
Liu SQ; Tian Q; Hedrick JL; Po Hui JH; Ee PL; Yang YY
Biomaterials; 2010 Oct; 31(28):7298-307. PubMed ID: 20615545
[TBL] [Abstract][Full Text] [Related]
36. Naphtho[1,2-b]furan-4,5-dione inactivates EGFR and PI3K/Akt signaling pathways in human lung adenocarcinoma A549 cells.
Su JC; Lin KL; Chien CM; Tseng CH; Chen YL; Chang LS; Lin SR
Life Sci; 2010 Jan; 86(5-6):207-13. PubMed ID: 20036260
[TBL] [Abstract][Full Text] [Related]
37. Molecular mechanisms underlying effects of epidermal growth factor receptor inhibition on invasion, proliferation, and angiogenesis in experimental glioma.
Guillamo JS; de Boüard S; Valable S; Marteau L; Leuraud P; Marie Y; Poupon MF; Parienti JJ; Raymond E; Peschanski M
Clin Cancer Res; 2009 Jun; 15(11):3697-704. PubMed ID: 19435839
[TBL] [Abstract][Full Text] [Related]
38. Hepatocyte viability and protein expression within hydrogel microstructures.
Itle LJ; Koh WG; Pishko MV
Biotechnol Prog; 2005; 21(3):926-32. PubMed ID: 15932275
[TBL] [Abstract][Full Text] [Related]
39. Buccal mucosa cells as in vivo model to evaluate gefitinib activity in patients with advanced non small cell lung cancer.
Loprevite M; Tiseo M; Chiaramondia M; Capelletti M; Bozzetti C; Bortesi B; Naldi N; Nizzoli R; Dadati P; Kunkl A; Zennaro D; Lagrasta C; Campanini N; Spiritelli E; Camisa R; Grossi F; Rindi G; Franciosi V; Ardizzoni A
Clin Cancer Res; 2007 Nov; 13(21):6518-26. PubMed ID: 17975165
[TBL] [Abstract][Full Text] [Related]
40. Synergistic therapeutic effects of Schiff's base cross-linked injectable hydrogels for local co-delivery of metformin and 5-fluorouracil in a mouse colon carcinoma model.
Wu X; He C; Wu Y; Chen X
Biomaterials; 2016 Jan; 75():148-162. PubMed ID: 26497429
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
